ClinicalTrials.gov record
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

ClinicalTrials.gov ID: NCT01284387

Public ClinicalTrials.gov record NCT01284387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 9, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease

Study identification

NCT ID
NCT01284387
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Enrollment
126 participants

Conditions and interventions

Interventions

  • ACC-001 (vanutide cridificar) Biological

Biological

Eligibility (public fields only)

Age range
50 Years to 89 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2010
Primary completion
Dec 31, 2013
Completion
Jan 31, 2014
Last update posted
Jan 4, 2015

2011 – 2014

United States locations

U.S. sites
25
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
Janssen AI Investigational Site Sun City Arizona 33613
Janssen AI Investigational Site La Jolla California 92093
Janssen AI Investigational Site Long Beach California 90806
Janssen AI Investigational Site Los Angeles California 90095
Janssen AI Investigational Site Oxnard California 93030
Janssen AI Investigational Site San Diego California 92103
Janssen AI Investigational Site San Francisco California 94143
Janssen AI Investigational Site Washington D.C. District of Columbia 20057
Janssen AI Investigational Site Miami Florida 33137
Janssen AI Investigational Site Miami Florida 33410
Janssen AI Investigational Site Ocala Florida 34471
Janssen AI Investigational Site Orlando Florida 32806
Janssen AI Investigational Site Sunrise Florida 33351
Janssen AI Investigational Site Tampa Florida 33609
Janssen AI Investigational Site Tampa Florida 33617
Janssen AI Investigational Site West Palm Beach Florida 33407
Janssen AI Investigational Site Scarborough Maine 04074
Janssen AI Investigational Site Boston Massachusetts 02115
Janssen AI Investigational Site Kansas City Missouri 64111
Janssen AI Investigational Site Las Vegas Nevada 89106
Janssen AI Investigational Site Princeton New Jersey 08540
Janssen AI Investigational Site Albany New York 12205
Janssen AI Investigational Site New York New York 10032
Janssen AI Investigational Site Centerville Ohio 45459
Janssen AI Investigational Site Oklahoma City Oklahoma 73112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01284387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 4, 2015 · Synced May 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01284387 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →